Vasopressin
Based on 7 publication(s) in Google Scholar
Vasopressin is a cyclic nonapeptide that is synthesized centrally in the hypothalamus. Vasopressin participates in the hypothalamic-pituitary-adrenal axis, and regulates pituitary corticotropin secretion by potentiating the stimulatory effects of corticotropin releasing factor. Vasopressin also can act as a neurotransmitter, exerting its action by binding to specific G protein-coupled receptors.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.65%
- CAS No.: 11000-17-2
- Formule: C46H65N15O12S2
- Masse moléculaire:1084.23
-
Stockage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Vasopressin
More
Customer Validation & Images
-
Cell Imaging/Staining
-
RT-PCR
-
Bio/Physico-chemical Assay
-
Cell Imaging/Staining
-
WB
Voir tous les produits spécifiques à Isoform Endogenous Metabolite
More
Activité biologique
|
Human Endogenous Metabolite |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A7R5 | IC50 |
10 nM
Compound: vasopressin, VS2
|
Tested for the TYR(Me)2 arginine-vasopressin as radioligand at 0.3 nM in A7r5 cells
Tested for the TYR(Me)2 arginine-vasopressin as radioligand at 0.3 nM in A7r5 cells
|
10.1016/S0960-894X(97)00050-4 |
| CHO | EC50 |
2 nM
Compound: AVP
|
Agonist activity at human vasopressin V1b receptor expressed CHO cells assessed as induction of phospholipase C activity after 15 mins by inositol phosphate accumulation assay
Agonist activity at human vasopressin V1b receptor expressed CHO cells assessed as induction of phospholipase C activity after 15 mins by inositol phosphate accumulation assay
|
[PMID: 21428295] |
| CHO | EC50 |
8.3 nM
Compound: AVP
|
Agonist activity at human oxytocin receptor expressed CHO cells assessed as induction of phospholipase C activity after 15 mins by inositol phosphate accumulation assay
Agonist activity at human oxytocin receptor expressed CHO cells assessed as induction of phospholipase C activity after 15 mins by inositol phosphate accumulation assay
|
[PMID: 21428295] |
| CHO-K1 | EC50 |
15 nM
Compound: 1, AVP, [Arg8]vasopressin
|
Agonist activity at human OT receptor expressed in CHO-K1 cells by luciferase reporter gene assay
Agonist activity at human OT receptor expressed in CHO-K1 cells by luciferase reporter gene assay
|
[PMID: 21688787] |
| CHO-K1 | EC50 |
22 nM
Compound: AVP
|
Agonist activity at human oxytocin receptor expressed in CHO-K1 cells after 5 hrs by firefly luciferase reporter gene assay
Agonist activity at human oxytocin receptor expressed in CHO-K1 cells after 5 hrs by firefly luciferase reporter gene assay
|
[PMID: 24874785] |
| COS-1 | EC50 |
41 nM
Compound: 2, AVP
|
Activity at oxytocin receptor expressed in COS1 cells assessed as IP-one generation by HTRF assay
Activity at oxytocin receptor expressed in COS1 cells assessed as IP-one generation by HTRF assay
|
[PMID: 21117646] |
| Flp-In-293 | EC50 |
4.3 nM
Compound: 1, AVP, [Arg8]vasopressin
|
Agonist activity at recombinant human vasopressin V1b receptor expressed in Flp-In-293 cells by luciferase reporter gene assay
Agonist activity at recombinant human vasopressin V1b receptor expressed in Flp-In-293 cells by luciferase reporter gene assay
|
[PMID: 21688787] |
| HEK293 | EC50 |
0.0035 nM
Compound: AVP
|
Agonist activity at recombinant human V1b receptor expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method
Agonist activity at recombinant human V1b receptor expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method
|
[PMID: 30896946] |
| HEK293 | EC50 |
0.004 nM
Compound: AVP
|
Agonist activity at recombinant human V1a receptor expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method
Agonist activity at recombinant human V1a receptor expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method
|
[PMID: 30896946] |
| HEK293 | EC50 |
0.05 nM
Compound: 1, AVP, [Arg8]vasopressin
|
Agonist activity at recombinant human vasopressin V2 receptor expressed in HEK293 cells by luciferase reporter gene assay
Agonist activity at recombinant human vasopressin V2 receptor expressed in HEK293 cells by luciferase reporter gene assay
|
[PMID: 21688787] |
| HEK293 | EC50 |
0.05 nM
Compound: AVP
|
Agonist activity at human vasopressin V2 expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay
Agonist activity at human vasopressin V2 expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay
|
[PMID: 24874785] |
| HEK293 | EC50 |
0.07 nM
Compound: 1, AVP, [Arg8]vasopressin
|
Agonist activity at recombinant rat vasopressin V1a receptor expressed in HEK293 cells by luciferase reporter gene assay
Agonist activity at recombinant rat vasopressin V1a receptor expressed in HEK293 cells by luciferase reporter gene assay
|
[PMID: 21688787] |
| HEK293 | EC50 |
0.1 nM
Compound: AVP
|
Agonist activity at recombinant human OTR expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method
Agonist activity at recombinant human OTR expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method
|
[PMID: 30896946] |
| HEK293 | EC50 |
0.24 nM
Compound: 1, AVP, [Arg8]vasopressin
|
Agonist activity at recombinant human vasopressin V1a receptor expressed in HEK293 cells by luciferase reporter gene assay
Agonist activity at recombinant human vasopressin V1a receptor expressed in HEK293 cells by luciferase reporter gene assay
|
[PMID: 21688787] |
| HEK293 | EC50 |
0.24 nM
Compound: AVP
|
Agonist activity at human vasopressin V1a expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay
Agonist activity at human vasopressin V1a expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay
|
[PMID: 24874785] |
| HEK293 | EC50 |
4.3 nM
Compound: AVP
|
Agonist activity at human vasopressin V1b expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay
Agonist activity at human vasopressin V1b expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay
|
[PMID: 24874785] |
Vasopressin (0.001-0.1 mg/kg; i.p.) potently increases adjacent lying, where rats meeting for the first time lie passively next to each other[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 11000-17-2
-
Appearance Solid
-
Masse moléculaire 1084.23
-
Formule C46H65N15O12S2
-
Color White to off-white
-
Synonyms
Arginine vasopressin; Antidiuretic hormone
-
Sequence
Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2 (Disulfide bridge: Cys1-Cys6)
-
Sequence Shortening
CYFQNCPRG-NH2 (Disulfide bridge: Cys1-Cys6)
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
2025 Nov 4;16(1):9734. PMID: 41188237 -
Nat Commun
Oxytocinergic input from the paraventricular nucleus to the nucleus accumbens core modulates methamphetamine-conditioned place preference. [Abstract]2025 May 23;16(1):4808. PMID: 40410135 -
Eur J Pharmacol
Melatonin activates the Mst1-Nrf2 signaling to alleviate cardiac hypertrophy in pulmonary arterial hypertension. [Abstract]2022 Oct 15:933:175262. PMID: 36100129
Vasopressin purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2022 Oct 15:933:175262. [Abstract]
Vasopressin (AVP) (10 μM; 48 h) increased neonatal primary rat cardiomyocyte surface areas.
Vasopressin purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2022 Oct 15:933:175262. [Abstract]
Vasopressin (AVP) (10 μM; 48 h) increased mRNA expression levels of cardiomyocyte hypertrophy markers BNP, TRPC6, and β-MHC in cardiomyocytes.
Vasopressin purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2022 Oct 15:933:175262. [Abstract]
Vasopressin (AVP) (10 μM; 48 h) markedly increased malondialdehyde (MDA) levels, an indicator of mitochondrial oxidative stress levels, in cardiomyocytes.
Vasopressin purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2022 Oct 15:933:175262. [Abstract]
Representative fluorescent JC-1 images and quantification of mitochondrial membrane potential (MMP) levels, in terms of the ratio of green (representing JC-1 monomers, and therefore depolarization and lowered MMP) to red (representing JC-1 aggregates) JC-1 fluorescence, were obtained in Vasopressin (AVP) (10 μM; 48 h)-treated cardiomyocytes.
Vasopressin purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2022 Oct 15:933:175262. [Abstract]
Vasopressin (AVP) (10 μM; 48 h) significantly decreased p-Mst1, the active phosphorylated form of Mst1, and nuclear Nrf2 protein levels in cardiomyocytes.
-
Endocrinology
Aspirin Suppresses Hepatic Glucagon Signaling Through Decreasing Production of Thromboxane A2. [Abstract]2023 Jan 9;164(3):bqac217. PMID: 36592127 -
Continence (Amst)
Endogenous vasopressin and vasopressin receptor 2 in bladder as anti-diuretic / anti-spasmodic targets for the treatment of multifactorial nocturia. [Abstract]2025 Dec:16:102292. PMID: 41503219 -
-
Solvant et solubilité
DMSO : 100 mg/mL (92.23 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 50 mg/mL (46.12 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (2.31 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (2.31 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 25 mg/mL (23.06 mM); Clear solution; Need ultrasonic and warming
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Pureté et documentation
-
Fiche technique (284 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Baribeau DA, et, al. Oxytocin and vasopressin: linking pituitary neuropeptides and their receptors to social neurocircuits. Front Neurosci. 2015 Sep 24;9:335. [Content Brief]
[2]. Ramos L, et, al. Acute prosocial effects of oxytocin and vasopressin when given alone or in combination with 3,4-methylenedioxymethamphetamine in rats: involvement of the V1A receptor. Neuropsychopharmacology. 2013 Oct;38(11):2249-59. [Content Brief]
[3]. Gal CSL, et, al. Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist. J Pharmacol Exp Ther. 2002 Mar;300(3):1122-30. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 0.9223 mL | 4.6116 mL | 9.2231 mL | 23.0578 mL |
| 5 mM | 0.1845 mL | 0.9223 mL | 1.8446 mL | 4.6116 mL | |
| 10 mM | 0.0922 mL | 0.4612 mL | 0.9223 mL | 2.3058 mL | |
| 15 mM | 0.0615 mL | 0.3074 mL | 0.6149 mL | 1.5372 mL | |
| 20 mM | 0.0461 mL | 0.2306 mL | 0.4612 mL | 1.1529 mL | |
| 25 mM | 0.0369 mL | 0.1845 mL | 0.3689 mL | 0.9223 mL | |
| 30 mM | 0.0307 mL | 0.1537 mL | 0.3074 mL | 0.7686 mL | |
| 40 mM | 0.0231 mL | 0.1153 mL | 0.2306 mL | 0.5764 mL | |
| DMSO | 50 mM | 0.0184 mL | 0.0922 mL | 0.1845 mL | 0.4612 mL |
| 60 mM | 0.0154 mL | 0.0769 mL | 0.1537 mL | 0.3843 mL | |
| 80 mM | 0.0115 mL | 0.0576 mL | 0.1153 mL | 0.2882 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Vasopressin Related Classifications
HY-B1811 Related Classifications
Powered by Bioz